Socioeconomic Status and Mortality
TO THE EDITOR: Alter and colleagues (1) address an important question regarding mediating factors that potentially account for the contribution of socioeconomic status to health care disparities. However, because of the potential social and political implications of these results, careful consideration should be given to several key issues that limit the authors' interpretations. First, it has been previously suggested that socioeconomic status is a multidimensional construct. Although operational definitions are numerous, most incorporate aspects of educational attainment, occupation, and social class. Use of self-reported income as a single measure to represent this construct therefore has the potential to markedly reduce strength of the intended "signal" and underestimate its association with the outcome of interest (2) . Second, the authors applied exclusion criteria that potentially attenuate an association between socioeconomic status and mortality and may introduce bias. The authors observe, for example, that patients with lower income had a significantly higher prevalence of cardiac risk factors and were less likely to receive specialty care. By eliminating from analysis those patients who died IN RESPONSE: We appreciate the comments of Drs. Shishehbor and Litaker. We agree that socioeconomic status is a multidimensional construct of which income serves as only 1 of many social measures. Although such limitations were acknowledged in our paper, our study did adjust for individual education, employment status, ethnicity, and social support. Adjustment for such variables partially accounted for some of the heterogeneous features of socioeconomic status. Furthermore, the inclusion of more elaborative social measures, although intriguing, would not have mitigated the importance of exploring the causal pathway factors that mediate income-mortality associations-associations that have been consistently observed in the literature and require explanation (1) .
We acknowledge that the exclusion of very high-risk patients (that is, those receiving mechanical ventilation or those who died before enrollment) may have introduced bias and attenuated the association between socioeconomic status and mortality. Unfortunately, the exclusion was unavoidable because income was ascertained by using self-administered surveys. Enrollment into the SESAMI (Socio-Economic and Acute Myocardial Infarction) study required patient consent, which also probably contributed to selection bias (2) . Consequently, the magnitude of association between income and mortality after acute myocardial infarction might have been less than otherwise expected had we been able to examine a more representative "real-world" population.
Nonetheless, the extent to which such limitations altered our results remains speculative. For example, available evidence suggests that wealth-health gradients are more likely to narrow, not widen, among elderly patients than among younger subgroups-subgroups that disproportionately make up higher-risk "real-world" populations (1, 3) . Of importance, the objective of our study was not to measure the true magnitude of association between income and mortality after acute myocardial infarction but to quantify the extent to which income-mortality associations were explained by traditional atherogenic or vascular factors, noncardiac comorbid conditions, and health service use. On the basis of our results and those of others (4), there is no reason to believe that age and cardiovascular risk factors would not have exerted similar explanatory effects on income-mortality associations if higher-risk populations had been examined.
To what extent, if any, can disparities between socioeconomic status and mortality rates be modified through intensive secondary prevention strategies? Are socially disadvantaged patients predestined to die after acute myocardial infarction (regardless of intensive secondary prevention initiatives) because of their baseline cardiovascular risk profiles at the time of presentation? These remain the pertinent questions for future study. Social-epidemiologic and health service research must now explore the impact of secondary preventive interventions to determine whether outcomes can be improved effectively and efficiently among high-risk populations in the real world. 
CLINICAL OBSERVATIONS

Acute Myocardial Infarction Associated with the Serotonin Syndrome
Background: The serotonin syndrome is an adverse drug reaction manifesting as mental status changes, autonomic hyperactivity, and neuromuscular abnormalities caused by excess stimulation of central nervous system and peripheral serotonin receptors. Diagnosis of the syndrome is based on characteristic clinical findings and history of exposure to serotonergic agents (1). Although peripheral serotonin activity is important for maintaining vascular tone, cardiac ischemia is not a typical complication of the serotonin syndrome or of selective serotonin reuptake inhibitor therapy. On the contrary, use of these agents has been postulated to decrease the risk for acute myocardial infarction (MI), possibly by inhibiting platelet activation (2) .
Objective: To describe a case of the serotonin syndrome causing an acute MI.
Case Report: A 31-year-old woman presented to the emergency department because of a change in mental status. She had a history of depression and bipolar disorder and had changed therapy from quetiapine to duloxetine 3 weeks before presentation. Her other medications were paroxetine, bupropion, and clonazepam. During the week before hospitalization, her mother described the patient as "twitchy." On the day of admission, the patient had vomited and was then found somnolent and confused. She had no history of intentional overdose, and no empty pill bottles were found at the scene. Findings on physical examination were consistent with the serotonin syndrome (1). Her vital signs were significant for a heart rate of 120 beats/min and blood pressure of 160/104 mm Hg. She was awake and confused with intermittent lucidity; she did not follow commands. She had nystagmus, a fine tremor, lower-extremity hyperreflexia, and inducible ankle clonus. Initial electrocardiographic findings were unremarkable. Results of laboratory studies were significant for a serum creatine kinase level of 1638 U/L with normal fractionation and a serum troponin I level of 3.83 g/L.
The patient was treated with aspirin, carvedilol, and lisinopril for cardiomyopathy. Over the next 3 days, her serum troponin I level decreased, and repeated electrocardiography showed inverted T waves in leads I, aVL, II, aVF, and V 3 to V 6 . She had septal, anterior, and lateral hypokinesis; ejection fraction was 0.30 on echocardiography. Her mental status gradually improved. She was discharged home after 4 days but returned 1 week later with pericarditis-like chest pain. During this second admission, a cardiac catheterization showed patent coronary arteries and an ejection fraction of 0.74. Discussion: Our patient had a cardiac biomarker leak with focal wall motion abnormalities that resolved after 1 week, consistent with myocardial stunning after acute MI. To our knowledge, the only case report of an acute MI associated with selective serotonin reuptake inhibitor therapy was a 69-year-old patient with diabetes and coronary artery disease who experienced an acute MI 5 days after starting venlafaxine therapy. This patient did not have clinical findings of the serotonin syndrome and, unlike our patient, had evidence of coronary atherosclerosis on cardiac catheterization (3) .
Excess serotonergic activity may be associated with ischemia, as evidenced by multiple reports of sumatriptan-induced acute MI (4). The serotonin syndrome may result in ischemia through constriction of coronary arteries because serotonin constricts most vascular beds. Paradoxically, serotonin dilates normal coronary arteries while constricting diseased ones (5). Endothelial 5-HT 1 receptors release vasodilatory endothelium-derived relaxing factor; consequently, vessels with atherosclerosis may not have this protective effect, which would result in unopposed 5-HT 2 receptor-mediated vasoconstriction (5). However, our patient must have had ischemia caused by vasospasm in the presence of normal coronary vasculature.
Conclusion: As the number of approved serotonergic agents increases and as more patients are given combination serotonergic therapy, the incidence of the serotonin syndrome will probably increase. Treatment is generally supportive; benzodiazepines (and possibly cyproheptadine) can be used to ameliorate serotonergic end-organ effects. Also, a conscious effort must be made not to prescribe new serotonergic agents for these patients because they may cause symptoms to worsen. Clinicians should consider the presence of myocardial ischemia in patients with serotonergic findings, particularly those known to have coronary artery disease or its risk factors.
